Tarlatamab Extends Survival in Second-Line Small Cell Lung Cancer, Expert Explains
Start here
Tarlatamab, a DLL3/CD3 bispecific T-cell engager, has shown improved outcomes as second-line treatment for small cell lung cancer. Its mechanism recruits T cells to DLL3-expressing tumor cells independent of MHC-I, bypassing a common route of immune escape. In the DeLLphi-304 trial, median overall survival rose from 8.3 months with chemotherapy to 13.6 months, the objective response rate increased from 20% to 35%, and the risk of death fell by 40%. The Chinese bridging study DeLLphi-307 showed an objective response rate of 39%. In a recent interview, Professor Chen Xiao discussed the drug's mechanism, efficacy, and safety management, including how clinicians should handle its toxicity profile in practice. Further details of that safety guidance and how the data translate into broader clinical use remain open questions.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comProfessor Chen Xiao Interprets Tarlatamab Second-Line Small Cell Lung Cancer Data and Safety Management
An interview with Professor Chen Xiao focuses on the mechanism, efficacy, and safety of tarlatamab in second-line small cell lung cancer. Its DLL3/CD3 bispecific T-cell engager (TCE) mechanism bypasses MHC-I restriction. In DeLLphi-304, median OS rose from 8.3 months with chemotherapy to 13.6 months, ORR from 20% to 35%, and the risk of death fell by 40%; the Chinese bridging study DeLLphi-307 showed an ORR of 39%.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 23 21:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.